Modular Medical (MODD)

Its strategy centres on modernising insulin pump design for both type 1 diabetes patients and the expanding group of type 2 diabetes patients who may benefit from device-based insulin management. While insulin pumps have long been used in diabetes care, adoption can be limited by cost, complexity, training requirements, and user concerns about wearing and operating a device. Modular Medical seeks to address those issues through product design aimed at ease of use, affordability, and practical everyday operation.

The company operates within the broader diabetes technology market, which includes insulin pumps, continuous glucose monitoring systems, smart pens, and automated insulin delivery platforms. This market is shaped by rising diabetes prevalence, growing use of connected health devices, and efforts by clinicians and payers to improve glucose control while reducing treatment burden.

As a development-stage company, Modular Medical’s commercial profile depends on product development milestones, regulatory progress, manufacturing readiness, clinical acceptance, and eventual market launch. Its revenue base is not yet comparable to established diabetes device manufacturers, but its focus is distinctive: it aims to expand pump therapy beyond the traditional early-adopter base and into a wider segment of insulin-using patients.

For investors, Modular Medical represents exposure to an emerging medical device company targeting a large and clinically important diabetes market with simplified insulin delivery technology.